Cargando…

Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells

BACKGROUND: Cirrhosis is a major health problem worldwide and new therapies are needed. Hepatic macrophages (hMø) have a pivotal role in liver fibrosis, being able to act in both its promotion and its resolution. It is well-known that mesenchymal stromal cells (MSCs) can modulate the immune/inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiore, Esteban, Malvicini, Mariana, Bayo, Juan, Peixoto, Estanislao, Atorrasagasti, Catalina, Sierra, Romina, Rodríguez, Marcelo, Gómez Bustillo, Sofia, García, Mariana G., Aquino, Jorge B., Mazzolini, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120504/
https://www.ncbi.nlm.nih.gov/pubmed/27876093
http://dx.doi.org/10.1186/s13287-016-0424-y
_version_ 1782469254193348608
author Fiore, Esteban
Malvicini, Mariana
Bayo, Juan
Peixoto, Estanislao
Atorrasagasti, Catalina
Sierra, Romina
Rodríguez, Marcelo
Gómez Bustillo, Sofia
García, Mariana G.
Aquino, Jorge B.
Mazzolini, Guillermo
author_facet Fiore, Esteban
Malvicini, Mariana
Bayo, Juan
Peixoto, Estanislao
Atorrasagasti, Catalina
Sierra, Romina
Rodríguez, Marcelo
Gómez Bustillo, Sofia
García, Mariana G.
Aquino, Jorge B.
Mazzolini, Guillermo
author_sort Fiore, Esteban
collection PubMed
description BACKGROUND: Cirrhosis is a major health problem worldwide and new therapies are needed. Hepatic macrophages (hMø) have a pivotal role in liver fibrosis, being able to act in both its promotion and its resolution. It is well-known that mesenchymal stromal cells (MSCs) can modulate the immune/inflammatory cells. However, the effects of MSCs over hMø in the context of liver fibrosis remain unclear. We previously described evidence of the antifibrotic effects of in vivo applying MSCs, which were enhanced by forced overexpression of insulin-like growth factor 1 (AdIGF-I-MSCs). The aim of this work was to analyze the effect of MSCs on hMø behavior in the context of liver fibrosis resolution. METHODS: Fibrosis was induced in BALB/c mice by chronic administration of thioacetamide (8 weeks). In vivo gene expression analyses, in vitro experiments using hMø isolated from the nonparenchymal liver cells fraction, and in vivo experiments with depletion of Mø were performed. RESULTS: One day after treatment, hMø from fibrotic livers of MSCs-treated animals showed reduced pro-inflammatory and pro-fibrogenic gene expression profiles. These shifts were more pronounced in AdIGF-I-MSCs condition. This group showed a significant upregulation in the expression of arginase-1 and a higher downregulation of iNOS expression thus suggesting decreased levels of oxidative stress. An upregulation in IGF-I and HGF expression was observed in hMø from AdIGF-I-MSCs-treated mice suggesting a restorative phenotype in these cells. Factors secreted by hMø, preconditioned with MSCs supernatant, caused a reduction in the expression levels of hepatic stellate cells pro-fibrogenic and activation markers. Interestingly, hMø depletion abrogated the therapeutic effect achieved with AdIGF-I-MSCs therapy. Expression profile analyses for cell cycle markers were performed on fibrotic livers after treatment with AdIGF-I-MSCs and showed a significant regulation in genes related to DNA synthesis and repair quality control, cell cycle progression, and DNA damage/cellular stress compatible with early induction of pro-regenerative and hepatoprotective mechanisms. Moreover, depletion of hMø abrogated such effects on the expression of the most highly regulated genes. CONCLUSIONS: Our results indicate that AdIGF-I-MSCs are able to induce a pro-fibrotic to resolutive phenotype shift on hepatic macrophages, which is a key early event driving liver fibrosis amelioration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0424-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5120504
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51205042016-11-28 Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells Fiore, Esteban Malvicini, Mariana Bayo, Juan Peixoto, Estanislao Atorrasagasti, Catalina Sierra, Romina Rodríguez, Marcelo Gómez Bustillo, Sofia García, Mariana G. Aquino, Jorge B. Mazzolini, Guillermo Stem Cell Res Ther Research BACKGROUND: Cirrhosis is a major health problem worldwide and new therapies are needed. Hepatic macrophages (hMø) have a pivotal role in liver fibrosis, being able to act in both its promotion and its resolution. It is well-known that mesenchymal stromal cells (MSCs) can modulate the immune/inflammatory cells. However, the effects of MSCs over hMø in the context of liver fibrosis remain unclear. We previously described evidence of the antifibrotic effects of in vivo applying MSCs, which were enhanced by forced overexpression of insulin-like growth factor 1 (AdIGF-I-MSCs). The aim of this work was to analyze the effect of MSCs on hMø behavior in the context of liver fibrosis resolution. METHODS: Fibrosis was induced in BALB/c mice by chronic administration of thioacetamide (8 weeks). In vivo gene expression analyses, in vitro experiments using hMø isolated from the nonparenchymal liver cells fraction, and in vivo experiments with depletion of Mø were performed. RESULTS: One day after treatment, hMø from fibrotic livers of MSCs-treated animals showed reduced pro-inflammatory and pro-fibrogenic gene expression profiles. These shifts were more pronounced in AdIGF-I-MSCs condition. This group showed a significant upregulation in the expression of arginase-1 and a higher downregulation of iNOS expression thus suggesting decreased levels of oxidative stress. An upregulation in IGF-I and HGF expression was observed in hMø from AdIGF-I-MSCs-treated mice suggesting a restorative phenotype in these cells. Factors secreted by hMø, preconditioned with MSCs supernatant, caused a reduction in the expression levels of hepatic stellate cells pro-fibrogenic and activation markers. Interestingly, hMø depletion abrogated the therapeutic effect achieved with AdIGF-I-MSCs therapy. Expression profile analyses for cell cycle markers were performed on fibrotic livers after treatment with AdIGF-I-MSCs and showed a significant regulation in genes related to DNA synthesis and repair quality control, cell cycle progression, and DNA damage/cellular stress compatible with early induction of pro-regenerative and hepatoprotective mechanisms. Moreover, depletion of hMø abrogated such effects on the expression of the most highly regulated genes. CONCLUSIONS: Our results indicate that AdIGF-I-MSCs are able to induce a pro-fibrotic to resolutive phenotype shift on hepatic macrophages, which is a key early event driving liver fibrosis amelioration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0424-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-22 /pmc/articles/PMC5120504/ /pubmed/27876093 http://dx.doi.org/10.1186/s13287-016-0424-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fiore, Esteban
Malvicini, Mariana
Bayo, Juan
Peixoto, Estanislao
Atorrasagasti, Catalina
Sierra, Romina
Rodríguez, Marcelo
Gómez Bustillo, Sofia
García, Mariana G.
Aquino, Jorge B.
Mazzolini, Guillermo
Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title_full Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title_fullStr Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title_full_unstemmed Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title_short Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells
title_sort involvement of hepatic macrophages in the antifibrotic effect of igf-i-overexpressing mesenchymal stromal cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120504/
https://www.ncbi.nlm.nih.gov/pubmed/27876093
http://dx.doi.org/10.1186/s13287-016-0424-y
work_keys_str_mv AT fioreesteban involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT malvicinimariana involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT bayojuan involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT peixotoestanislao involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT atorrasagasticatalina involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT sierraromina involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT rodriguezmarcelo involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT gomezbustillosofia involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT garciamarianag involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT aquinojorgeb involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells
AT mazzoliniguillermo involvementofhepaticmacrophagesintheantifibroticeffectofigfioverexpressingmesenchymalstromalcells